- Home
- NTRA
NTRA
Natera Inc.
as 11-10-2025 3:22pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 27.0B | IPO Year: | 2015 |
| Target Price: | $208.94 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $125.38 - $210.77 | Next Earning Date: | 11-06-2025 |
| Revenue: | $2,116,676,000 | Revenue Growth: | 38.17% |
| Revenue Growth (this year): | 25.7% | Revenue Growth (next year): | 15.42% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Nov 4 '25 | Sell | $200.73 | 22,900 | $4,591,674.04 | 2,286,554 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Nov 3 '25 | Sell | $198.96 | 3,000 | $595,810.04 | 112,061 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Nov 3 '25 | Sell | $200.00 | 17,100 | $3,420,003.42 | 2,286,554 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 3 '25 | Sell | $200.07 | 4,000 | $800,273.60 | 26,032 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Nov 3 '25 | Sell | $199.00 | 160,703 | $32,133,980.76 | 144,816 | |
| Marcus Gail Boxer | NTRA | Director | Nov 3 '25 | Sell | $198.71 | 122 | $24,242.62 | 5,762 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Oct 29 '25 | Sell | $190.35 | 1,867 | $355,924.59 | 65,693 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Oct 28 '25 | Sell | $191.46 | 1,198 | $229,371.36 | 112,061 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Oct 28 '25 | Sell | $191.46 | 1,058 | $202,566.69 | 201,699 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Oct 28 '25 | Sell | $191.46 | 928 | $177,676.64 | 150,699 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Natera Insider Sold Shares Worth $4,591,674, According to a Recent SEC Filing
StockStory
6 days ago
Natera (NTRA) Reports Earnings Tomorrow: What To Expect
StockStory
8 days ago
2 Unpopular Stocks That Should Get More Attention and 1 We Ignore
MT Newswires
11 days ago
Natera Expands Fetal Testing Tool to Include 20 Genes
Business Wire
11 days ago
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
Simply Wall St.
12 days ago
High Growth Tech Stocks To Watch In US This October 2025
Business Wire
12 days ago
Natera to Report its Third Quarter Results on November 6, 2025
Business Wire
14 days ago
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.